Growth Hormone Replacement Therapy in Heart Failure With Reduced Ejection Fraction: A Randomized, Double-Blind, Placebo-Controlled Trial.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

Who Took Part

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

Consecutive patients with HFrEF in NYHA functional class I/II/III and concomitant GHD were recruited.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group a baseline to be compared against.

The primary endpoint was peak oxygen consumption (VO2).

Secondary endpoints included hospitalizations, end-systolic left ventricular volumes, N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, health-related quality of life score, and muscle strength (handgrip).

What Was Measured

The subject headings attached to it are Heart Failure, Stroke Volume, Hormone Replacement Therapy, Quality of Life, Human Growth Hormone, Oxygen Consumption and Peptide Fragments.

The authors tagged it with the keywords cardiac function, cardiopulmonary performance, growth hormone deficiency and treatment.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The abstract goes on to report its results in about 10 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2025 (JACC. Heart failure), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.